PepGen Achieves Record Splicing Correction in Dystrophy Patients, Stock Price Soars 100%
Stock Performance: PepGen Inc. (NASDAQ: PEPG) saw its stock surge by 122.18% to $5.91, with a trading volume of 53.04 million shares, significantly higher than its average volume of 943.2 thousand.
Clinical Study Results: The company released promising data from its FREEDOM-DM1 Phase 1 study, showing a mean splicing correction of 53.7% in patients receiving a 15 mg/kg dose of PGN-EDODM1, with all patients responding positively to the treatment.
Trade with 70% Backtested Accuracy
Analyst Views on PEPG
About PEPG
About the author
PepGen Appoints New Chief Business Officer with 160,000 Stock Options Grant
- Executive Appointment: PepGen Inc. appointed Joseph Vittiglio as Chief Business and Legal Officer, granting him 160,000 non-qualified stock options under the 2024 Inducement Plan, with an exercise price of $5.59 per share, reflecting the company's commitment to strengthening its executive team.
- Stock Option Structure: The stock options have a ten-year term and are scheduled to vest over four years, with 25% vesting on the one-year anniversary of Vittiglio's employment and the remainder vesting in equal monthly installments, aimed at incentivizing his long-term service to the company.
- Plan Background: This grant is made under PepGen's 2024 Inducement Plan, adopted by the Board in August 2024, in accordance with Nasdaq Listing Rule 5635(c)(4), indicating the company's strategic intent to attract top talent.
- Company Vision: PepGen is focused on advancing next-generation oligonucleotide therapies to transform the treatment of severe neuromuscular and neurological diseases, and Vittiglio's addition is expected to contribute significantly to achieving this vision.
Meihua International Medical Technologies, Fly-E Group, and Other Major Stocks Decline in Pre-Market Trading on Monday
U.S. Stock Futures: U.S. stock futures showed mixed results, with Dow futures down approximately 0.1% on Monday morning.
Meihua International Medical Technologies: Shares of Meihua International Medical Technologies fell 32.9% in pre-market trading after the announcement of its delisting from Nasdaq.
Other Notable Stock Movements: Several other stocks experienced significant declines in pre-market trading, including SMX down 17.2%, Gulf Resources down 16.1%, and Wheeler Real Estate down 16.1%.
Market Reactions: The market saw various stocks decline after previous gains, with Fly-E Group and Ecarx Holdings also reporting notable drops due to regulatory issues and market fluctuations.
PepGen Appoints Joseph Vittiglio as Chief Business and Legal Officer
- Executive Appointment: PepGen Inc. has appointed Joseph Vittiglio as Chief Business and Legal Officer, leveraging over 20 years of leadership experience in biotechnology to enhance the company's progress in complex transactions and strategic partnerships.
- Product Advancement: Vittiglio's expertise will support PepGen's anticipated 2026 readouts for the PGN-EDODM1 program, further advancing treatments for severe neuromuscular diseases.
- Financing Expertise: At bluebird bio, Vittiglio led over $400 million in financings, an experience that will significantly bolster PepGen's capital operations and market expansion efforts.
- Intellectual Property Management: During his tenure at Finch Therapeutics, he oversaw a global IP portfolio of more than 50 patent families, which is expected to enhance PepGen's intellectual property protection capabilities in developing new therapies.
Sarepta's Shares Climb Following Encouraging News on DM1 Treatment
Sarepta Therapeutics' Stock Surge: Shares of Sarepta Therapeutics rose 7% following positive updates on its phase I/II study of SRP-1003, a potential treatment for type 1 myotonic dystrophy, including successful patient enrollment and safety committee approval.
Milestone Payments and Partnerships: The announcement triggered a $200 million milestone payment to Arrowhead Pharmaceuticals, part of a multi-billion-dollar licensing deal, with Sarepta having previously made a $100 million payment earlier this year.
Investor Sentiment: Despite the stock's significant decline of nearly 85% year-to-date, investor optimism has increased due to the positive study updates, contrasting with challenges faced by other companies in the same therapeutic area.
Future Developments: Sarepta is currently dosing patients in the fourth cohort of the study and plans to begin the fifth cohort in early 2026, with initial data expected early next year for SRP-1003 and other clinical-stage programs.
PepGen (PEPG) Price Target Raised by 17.65% to $10.20
Price Target Update: The average one-year price target for PepGen has been revised to $10.20 per share, reflecting a 17.65% increase from the previous estimate of $8.67, with a range from $3.03 to $21.00 per share.
Fund Sentiment: There are 159 funds reporting positions in PepGen, with a 7.43% increase in ownership over the last quarter, and total shares owned by institutions rising by 124.38% to 54,560K shares.
Major Shareholders: Ra Capital Management and Viking Global Investors significantly increased their holdings in PepGen, with Ra Capital raising its ownership by 46.72% and Viking by 57.43% over the last quarter.
Market Outlook: The put/call ratio for PepGen is 0.40, indicating a bullish sentiment among investors, while Fintel provides comprehensive investment research and data for individual investors and small hedge funds.
Dyne and PepGen Surge as Likely Winners from Novartis/Avidity Agreement
Market Reaction: Dyne Therapeutics and PepGen saw significant stock increases of approximately 41% and 21%, respectively, following Novartis' $12 billion acquisition of Avidity Biosciences.
Avidity's Developments: Avidity is advancing treatments for rare muscular dystrophies, including Del-zota for Duchenne muscular dystrophy and other candidates for myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy.
Dyne's Pipeline: Dyne Therapeutics is working on two candidates for myotonic dystrophy type 1, utilizing its proprietary FORCE platform, with data expected by mid-2026.
PepGen's Trials: PepGen is developing PGN-EDODM1 for myotonic dystrophy type 1 and is currently recruiting for two clinical trials, one in phase 1 and another in phase 2.
PepGen Appoints New Chief Business Officer with 160,000 Stock Options Grant
- Executive Appointment: PepGen Inc. appointed Joseph Vittiglio as Chief Business and Legal Officer, granting him 160,000 non-qualified stock options under the 2024 Inducement Plan, with an exercise price of $5.59 per share, reflecting the company's commitment to strengthening its executive team.
- Stock Option Structure: The stock options have a ten-year term and are scheduled to vest over four years, with 25% vesting on the one-year anniversary of Vittiglio's employment and the remainder vesting in equal monthly installments, aimed at incentivizing his long-term service to the company.
- Plan Background: This grant is made under PepGen's 2024 Inducement Plan, adopted by the Board in August 2024, in accordance with Nasdaq Listing Rule 5635(c)(4), indicating the company's strategic intent to attract top talent.
- Company Vision: PepGen is focused on advancing next-generation oligonucleotide therapies to transform the treatment of severe neuromuscular and neurological diseases, and Vittiglio's addition is expected to contribute significantly to achieving this vision.
Meihua International Medical Technologies, Fly-E Group, and Other Major Stocks Decline in Pre-Market Trading on Monday
U.S. Stock Futures: U.S. stock futures showed mixed results, with Dow futures down approximately 0.1% on Monday morning.
Meihua International Medical Technologies: Shares of Meihua International Medical Technologies fell 32.9% in pre-market trading after the announcement of its delisting from Nasdaq.
Other Notable Stock Movements: Several other stocks experienced significant declines in pre-market trading, including SMX down 17.2%, Gulf Resources down 16.1%, and Wheeler Real Estate down 16.1%.
Market Reactions: The market saw various stocks decline after previous gains, with Fly-E Group and Ecarx Holdings also reporting notable drops due to regulatory issues and market fluctuations.
PepGen Appoints Joseph Vittiglio as Chief Business and Legal Officer
- Executive Appointment: PepGen Inc. has appointed Joseph Vittiglio as Chief Business and Legal Officer, leveraging over 20 years of leadership experience in biotechnology to enhance the company's progress in complex transactions and strategic partnerships.
- Product Advancement: Vittiglio's expertise will support PepGen's anticipated 2026 readouts for the PGN-EDODM1 program, further advancing treatments for severe neuromuscular diseases.
- Financing Expertise: At bluebird bio, Vittiglio led over $400 million in financings, an experience that will significantly bolster PepGen's capital operations and market expansion efforts.
- Intellectual Property Management: During his tenure at Finch Therapeutics, he oversaw a global IP portfolio of more than 50 patent families, which is expected to enhance PepGen's intellectual property protection capabilities in developing new therapies.
Sarepta's Shares Climb Following Encouraging News on DM1 Treatment
Sarepta Therapeutics' Stock Surge: Shares of Sarepta Therapeutics rose 7% following positive updates on its phase I/II study of SRP-1003, a potential treatment for type 1 myotonic dystrophy, including successful patient enrollment and safety committee approval.
Milestone Payments and Partnerships: The announcement triggered a $200 million milestone payment to Arrowhead Pharmaceuticals, part of a multi-billion-dollar licensing deal, with Sarepta having previously made a $100 million payment earlier this year.
Investor Sentiment: Despite the stock's significant decline of nearly 85% year-to-date, investor optimism has increased due to the positive study updates, contrasting with challenges faced by other companies in the same therapeutic area.
Future Developments: Sarepta is currently dosing patients in the fourth cohort of the study and plans to begin the fifth cohort in early 2026, with initial data expected early next year for SRP-1003 and other clinical-stage programs.
PepGen (PEPG) Price Target Raised by 17.65% to $10.20
Price Target Update: The average one-year price target for PepGen has been revised to $10.20 per share, reflecting a 17.65% increase from the previous estimate of $8.67, with a range from $3.03 to $21.00 per share.
Fund Sentiment: There are 159 funds reporting positions in PepGen, with a 7.43% increase in ownership over the last quarter, and total shares owned by institutions rising by 124.38% to 54,560K shares.
Major Shareholders: Ra Capital Management and Viking Global Investors significantly increased their holdings in PepGen, with Ra Capital raising its ownership by 46.72% and Viking by 57.43% over the last quarter.
Market Outlook: The put/call ratio for PepGen is 0.40, indicating a bullish sentiment among investors, while Fintel provides comprehensive investment research and data for individual investors and small hedge funds.
Dyne and PepGen Surge as Likely Winners from Novartis/Avidity Agreement
Market Reaction: Dyne Therapeutics and PepGen saw significant stock increases of approximately 41% and 21%, respectively, following Novartis' $12 billion acquisition of Avidity Biosciences.
Avidity's Developments: Avidity is advancing treatments for rare muscular dystrophies, including Del-zota for Duchenne muscular dystrophy and other candidates for myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy.
Dyne's Pipeline: Dyne Therapeutics is working on two candidates for myotonic dystrophy type 1, utilizing its proprietary FORCE platform, with data expected by mid-2026.
PepGen's Trials: PepGen is developing PGN-EDODM1 for myotonic dystrophy type 1 and is currently recruiting for two clinical trials, one in phase 1 and another in phase 2.
